{
  "id": "adv_mhgap#risk_safety_4d9028a2",
  "content": "on minor congenital malformations available.\nFurther information on contraception is available\ny The risk of major congenital malformation was\nin the WHO fact sheet on family planning and\nnot significantly higher in infants of women taking\ncontraceptive methods (185). They must be provided\nlamotrigine (OR = 0.96; 95% CI: 0.72 to 1.25) or\nwith information on pregnancy prevention and risks\nlevetiracetam (OR = 0.72; 95% CI: 0.43 to 1.16). No\nassociated with use of sodium valproate during\ninformation on minor congenital malformations is\npregnancy, and referred for contraceptive advice\navailable.\nif they are not using effective contraception. When\ny There were no data on the teratogenic effect of\nchoosing the contraception method, individual\nlacosamide.\ncircumstances should be evaluated in each case,\ny There were no high-quality studies identified on\ninvolving the woman in the discussion to guarantee\nthe side-effects related to ASM exposure exclusively\nher engagement and compliance with the\nthrough breast-milk and the 2015 recommendation\nchosen measures.\nhas been validated by the GDG.\ny If a woman taking sodium valproate is planning\ny Due to the high risk of teratogenic effect with\nto become pregnant, a person trained in the\nvalproic acid, the GDG believed it was important",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "relationships",
      "risk_safety",
      "screening_cues",
      "referral",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Risk Safety on minor congenital malformations available.\nFurther information on contraception is available\ny The risk of major congenital malformation was\nin the WHO fact sheet on family planning and\nnot significantly higher in infants of women taking\ncontraceptive methods (185). They must be provided\nlamotrigine (OR = 0.96; 95% CI: 0.72 to 1.25) or\nwith information on pregnancy prevention and risks\nlevetiracetam (OR = 0.72; 95% CI: 0.43 to 1.16). No\nassociated with use of sodium valproate during\ninformation on minor congenital malformations is\npregnancy, and referred for contraceptive advice\navailable.\nif they are not using effective contraception. When\ny There were no data on the teratogenic effect of\nchoosing the contraception method, individual\nlacosamide.\ncircumstances should be evaluated in each case,\ny There were no high-quality studies identified on\ninvolving the woman in the discussion to guarantee\nthe side-effects related to ASM exposure exclusively\nher engagement and compliance with the\nthrough breast-milk and the 2015 recommendation\nchosen measures.\nhas been validated by the GDG.\ny If a woman taking sodium valproate is planning\ny Due to the high risk of teratogenic effect with\nto become pregnant, a person trained in the\nvalproic acid, the GDG believed it was important On minor congenital malformations available. further information on contraception is available\ny the nguy cơ of major congenital malformation was\nin the who fact sheet on family planning and\nnot significantly higher in i..."
}